lonafarnib has been researched along with gilteritinib in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (gilteritinib) | Trials (gilteritinib) | Recent Studies (post-2010) (gilteritinib) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 135 | 12 | 132 |
| Protein | Taxonomy | lonafarnib (IC50) | gilteritinib (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.76 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.0007 | |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0003 | |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | 0.0035 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0003 | |
| Transcription factor ETV6 | Homo sapiens (human) | 0.0085 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0036 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
1 review(s) available for lonafarnib and gilteritinib
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |